Vor Biopharma Inc. (VOR)

Vor Biopharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	81.95	31.36	57.71	119.8	48.54
Short-Term Investments	9.98	105.82	172.54	87.67	-
Cash & Short-Term Investments	91.93	137.18	230.25	207.47	48.54
Cash Growth	-32.99%	-40.42%	10.98%	327.43%	650.68%
Prepaid Expenses	4.2	3.15	4.37	4.84	0.47
Other Current Assets	0.38	0.48	2.34	2.09	0.1
Total Current Assets	96.51	140.8	236.95	214.4	49.11
Property, Plant & Equipment	41.59	50.1	57.08	22.52	21.85
Other Long-Term Assets	4.8	7.23	5.34	5.67	4.96
Total Assets	142.89	198.13	299.37	242.59	75.91
Accounts Payable	1.51	0.82	1.77	1.55	2.36
Accrued Expenses	12.89	10.93	8.08	6.34	6.26
Current Portion of Leases	4.22	3.83	3.27	1.84	0.86
Other Current Liabilities	-	-	-	0.43	0.72
Total Current Liabilities	18.61	15.57	13.12	10.15	10.21
Long-Term Leases	27.62	31.83	35.64	16.17	17.43
Total Liabilities	46.23	47.4	48.76	26.33	27.64
Common Stock	0.01	0.01	0.01	0	0
Additional Paid-In Capital	553.62	490.87	473.59	346.38	2.16
Retained Earnings	-456.99	-340.08	-222.22	-130.12	-61.22
Comprehensive Income & Other	0.02	-0.08	-0.77	-	-
Total Common Equity	96.66	150.72	250.61	216.26	-59.07
Shareholders' Equity	96.66	150.72	250.61	216.26	48.27
Total Liabilities & Equity	142.89	198.13	299.37	242.59	75.91
Total Debt	31.83	35.66	38.91	18.01	18.29
Net Cash (Debt)	60.1	101.52	191.33	189.46	30.25
Net Cash Growth	-40.80%	-46.94%	0.99%	526.38%	367.77%
Net Cash Per Share	0.87	1.51	4.84	5.67	141.56
Filing Date Shares Outstanding	124.85	68.17	66.37	37.49	37.13
Total Common Shares Outstanding	124.78	67.89	66	37.17	0.51
Working Capital	77.9	125.23	223.83	204.25	38.9
Book Value Per Share	0.77	2.22	3.80	5.82	-116.94
Tangible Book Value	96.66	150.72	250.61	216.26	-59.07
Tangible Book Value Per Share	0.77	2.22	3.80	5.82	-116.94
Machinery	17.15	17.4	15.64	8.77	5.45
Construction In Progress	0.04	0.15	1.04	-	-

Updated Mar 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q